Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Str8Shuteron Nov 15, 2022 8:30am
77 Views
Post# 35099184

RE:From MD&A

RE:From MD&A Hey, 2018 just called.  They want their talking points back!!


LithLover wrote:
In the nine months of 2022, we have:
• Raised CAD 2.05M in a private placement
• Integrated CareOncology into StageZero and started scaling
• Launched AVRT in the UK
• Extended the availability of the COC Protocol into the European Union
• Launched COC Plus Program Worldwide
• CareOncology UK approaches breakeven
• Expanded marketing programs and new lab partners for Aristotle into multiple new cities in the US
• Engaged with employers with Aristotle + AVRT cancer screening program
• Deepened the Aristotle test offering with the addition of ColoRectal Cancer by stage ie early vs late
• Participated in several conferences eg HC Wainwright, keynote speaker at S.E.E. Summit
Successfully submitted proposal offerings to multiple first responder organizations and begun testing first responders
 
Continuing through the next twelve months, the Company will be focusing on the following:
 
• Drive revenue growth by significantly increasing spend against promotion.
• Position Aristotle + AVRT as the #1 program for early cancer detection for employers with at-risk workforces.
• Fully implement current partnerships with key employer groups using Aristotle + AVRT.
• Present data and analysis with respect to at-risk workforces to demonstrate benefit of Aristotle + AVRT
• Broaden relationships with key oncologists and clinics to enhance the reach of CareOncology/Aristotle with a strong focus on HealthCare Systems in multiple key cities.
• Continue to broaden and deepen Aristotle eg CRC. lung and breast cancer staging.
• Partner and launch in key geographic regions world-wide.


<< Previous
Bullboard Posts
Next >>